vs
Arcturus Therapeutics Holdings Inc.（ARCT）与RIVERVIEW BANCORP INC（RVSB）财务数据对比。点击上方公司名可切换其他公司
RIVERVIEW BANCORP INC的季度营收约是Arcturus Therapeutics Holdings Inc.的2.0倍（$14.0M vs $7.2M），RIVERVIEW BANCORP INC同比增速更快（10.4% vs -68.4%），RIVERVIEW BANCORP INC自由现金流更多（$-736.0K vs $-74.5M），过去两年RIVERVIEW BANCORP INC的营收复合增速更高（24.6% vs -56.5%）
Arcturus Therapeutics Holdings Inc.是一家专注于RNA药物研发的美国生物科技企业，核心业务覆盖罕见病与传染病领域药物的研发、开发与商业化。该公司自主研发了专属脂质纳米颗粒递送技术，可用于递送小干扰RNA、信使RNA、基因编辑RNA、DNA、反义寡核苷酸、微小RNA等多种核酸药物。
Riverview Bancorp Inc.是一家总部位于美国的银行控股公司，主营个人与商业银行业务，服务覆盖太平洋西北地区，提供存款、消费贷款、住房抵押贷款、商业信贷及小企业金融等产品，服务零售客户与本地企业群体。
ARCT vs RVSB — 直观对比
营收规模更大
RVSB
是对方的2.0倍
$7.2M
营收增速更快
RVSB
高出78.8%
-68.4%
自由现金流更多
RVSB
多$73.8M
$-74.5M
两年增速更快
RVSB
近两年复合增速
-56.5%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $7.2M | $14.0M |
| 净利润 | — | $1.4M |
| 毛利率 | — | — |
| 营业利润率 | — | 12.4% |
| 净利率 | — | 9.8% |
| 营收同比 | -68.4% | 10.4% |
| 净利润同比 | 3.1% | 11.8% |
| 每股收益（稀释后） | — | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ARCTRVSB
| Q4 25 | $7.2M | $14.0M | ||
| Q3 25 | $17.2M | $13.6M | ||
| Q2 25 | $28.3M | $13.3M | ||
| Q1 25 | $29.4M | $12.9M | ||
| Q4 24 | $22.8M | $12.7M | ||
| Q3 24 | $41.7M | $12.8M | ||
| Q2 24 | $49.9M | $12.2M | ||
| Q1 24 | $38.0M | $9.0M |
净利润ARCTRVSB
| Q4 25 | — | $1.4M | ||
| Q3 25 | $-13.4M | $1.1M | ||
| Q2 25 | $-9.2M | $1.2M | ||
| Q1 25 | $-14.1M | $1.1M | ||
| Q4 24 | $-30.0M | $1.2M | ||
| Q3 24 | $-6.9M | $1.6M | ||
| Q2 24 | $-17.2M | $966.0K | ||
| Q1 24 | $-26.8M | $-3.0M |
营业利润率ARCTRVSB
| Q4 25 | — | 12.4% | ||
| Q3 25 | -96.3% | 10.2% | ||
| Q2 25 | -41.0% | 11.7% | ||
| Q1 25 | -57.3% | 11.3% | ||
| Q4 24 | -146.7% | 12.4% | ||
| Q3 24 | -25.8% | 15.5% | ||
| Q2 24 | -42.4% | 10.0% | ||
| Q1 24 | -80.0% | -47.5% |
净利率ARCTRVSB
| Q4 25 | — | 9.8% | ||
| Q3 25 | -78.4% | 8.1% | ||
| Q2 25 | -32.4% | 9.2% | ||
| Q1 25 | -47.9% | 8.9% | ||
| Q4 24 | -131.8% | 9.7% | ||
| Q3 24 | -16.6% | 12.2% | ||
| Q2 24 | -34.5% | 7.9% | ||
| Q1 24 | -70.5% | -34.7% |
每股收益（稀释后）ARCTRVSB
| Q4 25 | — | $0.07 | ||
| Q3 25 | $-0.49 | $0.05 | ||
| Q2 25 | $-0.34 | $0.06 | ||
| Q1 25 | $-0.52 | $0.05 | ||
| Q4 24 | $-1.10 | $0.06 | ||
| Q3 24 | $-0.26 | $0.07 | ||
| Q2 24 | $-0.64 | $0.05 | ||
| Q1 24 | $-1.00 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $230.9M | $28.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $214.0M | $164.2M |
| 总资产 | $271.1M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ARCTRVSB
| Q4 25 | $230.9M | $28.6M | ||
| Q3 25 | $180.4M | $32.8M | ||
| Q2 25 | $196.5M | $34.2M | ||
| Q1 25 | $216.9M | $29.4M | ||
| Q4 24 | $237.0M | $25.3M | ||
| Q3 24 | $237.2M | $31.0M | ||
| Q2 24 | $260.3M | $27.8M | ||
| Q1 24 | $288.4M | $23.6M |
股东权益ARCTRVSB
| Q4 25 | $214.0M | $164.2M | ||
| Q3 25 | $224.6M | $163.5M | ||
| Q2 25 | $231.1M | $162.0M | ||
| Q1 25 | $233.8M | $160.0M | ||
| Q4 24 | $241.0M | $158.3M | ||
| Q3 24 | $261.9M | $160.8M | ||
| Q2 24 | $258.6M | $155.9M | ||
| Q1 24 | $264.0M | $155.6M |
总资产ARCTRVSB
| Q4 25 | $271.1M | $1.5B | ||
| Q3 25 | $282.3M | $1.5B | ||
| Q2 25 | $309.3M | $1.5B | ||
| Q1 25 | $331.8M | $1.5B | ||
| Q4 24 | $344.1M | $1.5B | ||
| Q3 24 | $370.7M | $1.5B | ||
| Q2 24 | $388.6M | $1.5B | ||
| Q1 24 | $418.8M | $1.5B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-74.3M | $-506.0K |
| 自由现金流经营现金流 - 资本支出 | $-74.5M | $-736.0K |
| 自由现金流率自由现金流/营收 | -1035.2% | -5.2% |
| 资本支出强度资本支出/营收 | 3.2% | 1.6% |
| 现金转化率经营现金流/净利润 | — | -0.37× |
| 过去12个月自由现金流最近4个季度 | — | $20.4M |
8季度趋势，按日历期对齐
经营现金流ARCTRVSB
| Q4 25 | $-74.3M | $-506.0K | ||
| Q3 25 | $-17.2M | $16.8M | ||
| Q2 25 | $-5.8M | $-697.0K | ||
| Q1 25 | $-35.1M | $8.3M | ||
| Q4 24 | $-284.0K | $2.2M | ||
| Q3 24 | $-23.8M | $764.0K | ||
| Q2 24 | $-30.1M | $5.4M | ||
| Q1 24 | $-5.6M | $12.8M |
自由现金流ARCTRVSB
| Q4 25 | $-74.5M | $-736.0K | ||
| Q3 25 | $-17.3M | $16.4M | ||
| Q2 25 | — | $-773.0K | ||
| Q1 25 | $-35.3M | $5.6M | ||
| Q4 24 | — | $1.9M | ||
| Q3 24 | $-23.8M | $-1.4M | ||
| Q2 24 | $-30.5M | $5.3M | ||
| Q1 24 | $-5.8M | $7.1M |
自由现金流率ARCTRVSB
| Q4 25 | -1035.2% | -5.2% | ||
| Q3 25 | -101.1% | 120.1% | ||
| Q2 25 | — | -5.8% | ||
| Q1 25 | -120.1% | 43.1% | ||
| Q4 24 | — | 15.0% | ||
| Q3 24 | -57.2% | -11.3% | ||
| Q2 24 | -61.1% | 43.7% | ||
| Q1 24 | -15.3% | 79.0% |
资本支出强度ARCTRVSB
| Q4 25 | 3.2% | 1.6% | ||
| Q3 25 | 1.1% | 2.9% | ||
| Q2 25 | 0.0% | 0.6% | ||
| Q1 25 | 0.5% | 21.0% | ||
| Q4 24 | 0.0% | 2.4% | ||
| Q3 24 | 0.2% | 17.3% | ||
| Q2 24 | 0.7% | 0.9% | ||
| Q1 24 | 0.6% | 62.0% |
现金转化率ARCTRVSB
| Q4 25 | — | -0.37× | ||
| Q3 25 | — | 15.25× | ||
| Q2 25 | — | -0.57× | ||
| Q1 25 | — | 7.20× | ||
| Q4 24 | — | 1.79× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 5.63× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
